Adaptvac
AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
11
1 to 10 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
4
organic / mo
Sign up free to see all 5 verified contacts at Adaptvac
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- CF
Cyrielle Fougeroux
Team Leader · Science
EmailPhone - LG
Louise Goksøyr
Scientist, Project Lead · Science
EmailPhone - SH
Sanna Hentze Vestergaard
Laboratory Manager · Science
EmailPhone - SH
Sven Hagen
Scientist · Science
EmailPhone
Showing 4 of 5 verified contacts
Top roles at Adaptvac
5 distinct titles indexed · top 5 shown.
- 1laboratory manager
- 1research internship
- 1scientist
- 1scientist, project lead
- 1team leader
Sign up to unlock all 5 contacts at Adaptvac
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Adaptvac
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.